TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04502017

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASA plus Clopidogrel
Description: OAC (6 weeks) + DAPT (until 6 months) + ASA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Genetic-Tailored AntiThrombotic Strategy
Description: Half-Dose OAC or Clopidogrel in combination with ASA on the basis of CYP2C19 Genotype

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Half-Dose of novel OAC
Description: Half Dose of novel OAC post-device Implantation
Study: NCT04032184

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride toothpaste
Description: regimen using fluoride toothpaste

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fluoride toothpaste and chlorhexidine mouthwash
Description: regimen using fluoride toothpaste and chlorhexidine mouthwash

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fluoride toothpaste, chlorhexidine mouthwash, MI varnish
Description: regimen using fluoride toothpaste, chlorhexidine mouthwash, MI varnish
Study: NCT00515723

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risperidone
Description: randomized to 12 week trial of risperidone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: randomized to 12 week trial of olanzapine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: quetiapine
Description: randomized to 12 week trial of quetiapine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ziprasidone
Description: randomized to 12 week trial of ziprasidone.
Study: NCT02461953

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hemoperfusion apparatus

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hemoperfusion apparatus

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low flux dialyzer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low flux dialyzer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high flux dialyzer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high flux dialyzer
Study: NCT00701649

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYT006-AngQb
Description: s.c.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: s.c.
Study: NCT02923791

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim Hospira
Description: 5 consecutive daily doses (Days 1-5) in Period 1 and 1 dose (Day 1) in Period 2.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: US-Approved Neupogen
Description: 5 consecutive daily doses (Days 1-5) in Period 1 and 1 dose (Day 1) in Period 2.
Study: NCT01789047

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate
Description: Topiramate as adjunct to amantadine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amantadine
Description: Existing treatment for all participants
Study: NCT01815853

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemoradiotherapy
Description: Radiotherapy (45Gy/25f) + 3 cycles of XELOX Chemotherapy (Capecitabine 1000mg/m2, d1-14 + Oxaliplatin 130mg/m2 d1; 21-days/cycle)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant Chemotherapy
Description: 3 cycles of XELOX Chemotherapy (Capecitabine 1000mg/m2, d1-14 + Oxaliplatin 130mg/m2 d1; 21-days/cycle)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: R0 D2 Gastrectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: R0 D2 Gastrectomy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant Chemotherapy
Description: 3 cycles of XELOX Chemotherapy (Capecitabine 1000mg/m2, d1-14 + Oxaliplatin 130mg/m2 d1; 21-days/cycle)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant Chemotherapy
Description: 3 cycles of XELOX Chemotherapy (Capecitabine 1000mg/m2, d1-14 + Oxaliplatin 130mg/m2 d1; 21-days/cycle)
Study: NCT04199845

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PS128
Description: PS128 or placebo will be given twice daily for 8 weeks.
Study: NCT01789047

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amantadine
Description: Existing treatment for all participants
Study: NCT04213664

Intervention type: OTHER
Intervention: prognosis
Description: cancer and overall survival cancer specific survival cancer and recurrence-free survival cancer and disease-free survival lymphocyte to monocyte ratio in non-metastatic renal cancer and progression-free survival
Study: NCT04199845

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PS128
Description: PS128 or placebo will be given twice daily for 8 weeks.
Study: NCT01187381

Intervention type: DRUG
Intervention: Trastuzumab
Description: Trastuzumab according to local standard of care and in line with the current summary of product characteristics/ local guidelines
Study: NCT04367285

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensor-based Training
Description: Sensor-based Training consists of twelve sessions of upper limb training with PABLO®-Tyromotion. For each session the training consists in interactive-games based on virtual reality which allowed a task-oriented approach and a neurocognitive feedback. The exercises require precision tasks and one-dimensional and bidimensional reaction, allowing to train the attention, the strength control and movement control, the coordination and the movement precision. The interactive-games were chosen from those proposed by the Tyromotion PABLO® System.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Upper limb motor training
Description: Upper limb motor training, without robotic support. Subjects performed specific exercises aimed to recovery global upper limb functions, to control hand grasp and to improve hand's fine movements.
Study: NCT00576563

Intervention type: DRUG
Group type: OTHER
Intervention: FDG
Description: contrast medium
Study: NCT03762200

Intervention type: DEVICE
Group type: OTHER
Intervention: SURGICEL Powder
Description: SURGICEL Powder is a topical absorbable hemostatic treatment made of oxidized regenerated cellulose (ORC) - plant material
Study: NCT02153151

Intervention type: OTHER
Intervention: Cytology specimen
Description: Correlative studies

Intervention type: OTHER
Intervention: Laboratory biomarker analysis
Description: Correlative studies
Study: NCT05173389

Intervention type: OTHER
Group type: OTHER
Intervention: TechnoBody
Description: 1. Group-TechnoBody balance training (15 min / 5 days a week, 4 weeks) In the study, the first group will be included in the balance program with the TechnoBody device Patients will be applied 5 days of week~1. Exercise bike with visual feedback, which allows active-assisted or resistant work according to the condition of the patient, will be done in the lower limb for 10 minutes.~2. Nmes- (Neuromuscular electrical stimulation) will be applied to the hemiparetic limb for 10 minutes.~3. Bobath Method- 30 minutes

Intervention type: OTHER
Group type: OTHER
Intervention: Thera-Trainer
Description: 2. Group-Thera-Trainer balance training (15 min / 5 days a week, 4 weeks) the second group will be taken into the balance program with the Thera-Trainer device and the results of both groups will be compared after 4 weeks.~Patients will be applied 5 days of week~1. Exercise bike with visual feedback, which allows active-assisted or resistant work according to the condition of the patient, will be done in the lower limb for 10 minutes.~2. Nmes- (Neuromuscular electrical stimulation) will be applied to the hemiparetic limb for 10 minutes.~3. Bobath Method- 30 minutes
Study: NCT01728337

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dysport
Description: Dysport® was injected on the right side of the forehead and Xeomin® was injected on the left side of the forehead.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dysport
Description: Dysport® was injected on the right side of the forehead and Xeomin® was injected on the left side of the forehead.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xeomin
Description: Xeomin® was injected on the right side of the forehead and Dysport® was injected on the left side of the forehead

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xeomin
Description: Xeomin® was injected on the right side of the forehead and Dysport® was injected on the left side of the forehead
Study: NCT00384397

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Description: 0.5 mL, Intramuscular
Study: NCT04558892

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Study: NCT02078271

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FBDG group
Description: The group received food based dietary guidelines for complementary feeding

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FBDG group
Description: The group received food based dietary guidelines for complementary feeding

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stimulation
Description: The group received psychosocial stimulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stimulation
Description: The group received psychosocial stimulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combinded FBDG and stimulation
Description: The group received both FBDG and psychosocial stimulation

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Study: NCT02102048

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir
Study: NCT01681758

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IV fluid according to PPV
Description: intravenous fluids

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: fluids according to standard care
Study: NCT00964028

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix™-IPV/Hib
Description: Intramuscular, three doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix™-IPV/Hib
Description: Intramuscular, three doses
Study: NCT03471832

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stenfilcon A lens
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: narafilcon A lens
Description: contact lens
Study: NCT03074877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Check-Up
Description: The Family Check-Up (FCU) is a brief, family-based program to prevent Substance Use/Substance Use Disorder (SU/SUD) with replicated efficacy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Check-Up
Description: The Family Check-Up (FCU) is a brief, family-based program to prevent Substance Use/Substance Use Disorder (SU/SUD) with replicated efficacy
Study: NCT02646683

Intervention type: DRUG
Group type: OTHER
Intervention: vedolizumab
Study: NCT06519084

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home based exercise training
Description: Intervention: home based physical exercise performed 4 times a week, each session lasting 40 minutes each. Aerobic and muscular resistance exercises, using body weight and elastic bands.~The sessions were proposed through video classes, in total 12 video classes during the 12 weeks of physical training. Patients monitored their heart rate during exercise and wrote it down on spreadsheets that were monitored weekly.
Study: NCT04551677

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2020-2021 formulation
Description: Pharmaceutical form: Suspension for injection in a pre-filled syringe,~Route of administration: Intramuscular (IM)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2020-2021 formulation
Description: Pharmaceutical form: Suspension for injection in a pre-filled syringe,~Route of administration: Intramuscular (IM)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2020-2021 formulation
Description: Pharmaceutical form: Suspension for injection in a pre-filled syringe,~Route of administration: IM
Study: NCT02353364

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PGS
Description: Embryos screened by the validated NGS technology CNV-Seq
Study: NCT00896597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL972
Description: 2 mg NRL972 in 5 mL solution for injection administered as a 15-second intravenous injection on each of four occasions.
Study: NCT00777764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort I
Description: In sterile water for injection (SWFI), full concentration and 1:1000, 1:100, 1:10 dilutions of 125 mg/mL of standard solution of omalizumab and its excipients. Skin prick test of each dilution concentration of 1:1000, 1:100, 1:10 and full concentration and Intradermal tests of each dilution concentration of 1:1000, 1:100 and 1:10 were followed by 20 minutes of observation. For the skin prick test, participants were tested initially with positive control (histamine 6 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration.~For the intradermal test, participants were tested initially with positive control (histamine 0.1 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration.~Dilutions of omalizumab and its excipients were in SWFI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2
Description: In a saline solution, full concentration and 1:1000, 1:100, 1:10 dilutions of 125 mg/mL of standard solution of omalizumab and its excipients. Skin prick test of each dilution concentration of 1:1000, 1:100, 1:10 and full concentration and Intradermal tests of each dilution concentration of 1:100,000 and 1:10,000 were followed by 20 minutes of observation.~For the skin prick test, participants were tested initially by positive control (histamine 6 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration. For the intradermal test, participants were tested initially with positive control (histamine 0.1 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration.~Dilutions of omalizumab and its excipients were made in saline.
Study: NCT04353505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Intra-arterial delivery of Ketorolac in the internal maxillary artery, once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Intra-arterial delivery of Dexamethasone in the internal maxillary artery, once.
Study: NCT03255005

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endomina
Description: Endoscopic sleeve reduction

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endomina
Description: Endoscopic sleeve reduction

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Multidisciplinary follow-up
Study: NCT03342833

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blood flow restriction
Description: Occlusion of venous flow between bouts of HIIT training exercise

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Blood flow restriction
Description: Occlusion of venous flow between bouts of HIIT training exercise
Study: NCT03371147

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CancerLife
Description: CancerLife is a patient facing messaging app that gives cancer survivors and caregivers the ability to update family and friends of their health status through their existing social networks and at the same collect psychosocial and symptom reports that can be shared with the patients care team.
Study: NCT03402698

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: supplementation at a dose 1000 IU/d
Study: NCT04400110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin and Clavulanic Acid in Oral Dose Form
Description: 50 mg/kg three times daily administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin and Clavulanic Acid in Oral Dose Form
Description: 50 mg/kg three times daily administered orally
Study: NCT02092597

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gliclazide
Study: NCT01730950

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: Staring within 14 days of randomization, IV 10mg/kg every two weeks until disease progression.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Staring within 14 days of randomization, IV 10mg/kg every two weeks until disease progression.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Starting with second dose of bevacizumab, 35 Gy in 10 fractions of 3.5 Gy each delivered on consecutive treatment days (typically 5 fractions per week).
Study: NCT03963869

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Malaria Camps
Description: The Govt. of India Malaria Control Programme (MCP) of Odisha provides ITNs and IRS, and trains community health workers (ASHAs) on the diagnosis and treatment of malaria, providing them with antimalarial drugs so that malaria treatment is available even in remote villages. Faced with a persistent burden of malaria in forest villages, the MCP recently introduced malaria camps (MCs) combining focused screening and treatment in villages with intensified vector control. The program includes one round of testing and treatment for the whole village population before the monsoon season, followed by one round of screening and treating of fever cases only during the monsoon season.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Malaria Camps
Description: The Govt. of India Malaria Control Programme (MCP) of Odisha provides ITNs and IRS, and trains community health workers (ASHAs) on the diagnosis and treatment of malaria, providing them with antimalarial drugs so that malaria treatment is available even in remote villages. Faced with a persistent burden of malaria in forest villages, the MCP recently introduced malaria camps (MCs) combining focused screening and treatment in villages with intensified vector control. The program includes one round of testing and treatment for the whole village population before the monsoon season, followed by one round of screening and treating of fever cases only during the monsoon season.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Malaria Camps
Description: The Govt. of India Malaria Control Programme (MCP) of Odisha provides ITNs and IRS, and trains community health workers (ASHAs) on the diagnosis and treatment of malaria, providing them with antimalarial drugs so that malaria treatment is available even in remote villages. Faced with a persistent burden of malaria in forest villages, the MCP recently introduced malaria camps (MCs) combining focused screening and treatment in villages with intensified vector control. The program includes one round of testing and treatment for the whole village population before the monsoon season, followed by one round of screening and treating of fever cases only during the monsoon season.
Study: NCT03647904

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SEMS Project
Description: TThe intervention is a culmination of five empirically supported interventions: (1) The MS Wellness Program aimed at developing lifestyle strategies to enhance quality of living and cope with various aspects of MS; (2) The FACETS intervention, which aims to reduce fatigue and improve self-efficacy; (3) The Modified Story Memory technique, which improves new learning and memory; (4) The Speed of Processing training, which improves performance on measures of processing speed in persons with MS. Finally, the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders, a cognitive behavioral intervention, which improves psychological functioning and functional outcomes.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: SEMS Project
Description: TThe intervention is a culmination of five empirically supported interventions: (1) The MS Wellness Program aimed at developing lifestyle strategies to enhance quality of living and cope with various aspects of MS; (2) The FACETS intervention, which aims to reduce fatigue and improve self-efficacy; (3) The Modified Story Memory technique, which improves new learning and memory; (4) The Speed of Processing training, which improves performance on measures of processing speed in persons with MS. Finally, the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders, a cognitive behavioral intervention, which improves psychological functioning and functional outcomes.
Study: NCT01385748

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine Lauriad® 50µg
Description: 50µg muco-adhesive buccal tablet once day every day up to 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine Lauriad® 100µg
Description: 100µg muco-adhesive buccal tablets, once a day, every day up to 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Lauriad®
Description: placebo muco-adhesive buccal tablets, once a day, every day up to 8 weeks
Study: NCT02328118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: A week before 25-gauge vitrectomy, all subjects in Ranibizumab group will receive Ranibizumab 0.5mg/0.05 ml intravitreal injection. All patients in this group will receive Triamcinolone Acetonide(4mg/0.1ml) during operation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: A week before 25-gauge vitrectomy, all subjects in Triamcinolone Acetone group will receive Triamcinolone Acetone 4mg/0.1 ml intravitreal injection. All patients in this group will receive Triamcinolone Acetonide(4mg/0.1ml) during operation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: A week before 25-gauge vitrectomy, all subjects in Triamcinolone Acetone group will receive Triamcinolone Acetone 4mg/0.1 ml intravitreal injection. All patients in this group will receive Triamcinolone Acetonide(4mg/0.1ml) during operation.